Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M & A

Celgene is acquiring Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. The author analyzes the price per share and returns over each of the biotech ' s funding rounds.

Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Bruce Booth, Contributor Tags: NASDAQ:JUNO Source Type: news